By Zhibo Gai, Department of Clinical Pharmacology and Toxicology, University Hospital Zurich
By James Trevaskis, Principal Scientist & Head of In Vivo Pharmacology, MedImmune
By Jonathan Roth, Senior Director, In Vivo Pharmacology, Intercept Pharmaceuticals
By George O’Rourke, Managing Director, GO Biotech Consulting
Read this report for learnings from a pre-conference crash course on the foremost challenges in the NASH arena, exciting clinical updates from several phase 1 and 2 players in the ever-expanding NASH competitive landscape, and basic science galore from the world of preclinical NASH drug development.
Review discussion highlights from the meeting earlier this year.
“The goal of the three-day conference was to gather players from all corner of the growing NASH field to “help drug developers meet the unique challenges of developing a NASH drug,” but the agenda also featured many useful talks to bring attendees up to speed on the pathophysiology of the disease, areas of pressing need, and progress in drug development.”
Stephen F. Previs, Ph.D., Merck
Emil Chuang, VP, GI Therapeutic Area Head, Translational Medicine, Takeda
Get your solution in front of 150+ drug developers from 120+ organizations at the industry’s leading event for companies developing NASH candidates.
Download the partnership prospectus for a breakdown of exactly who you will meet, and the various opportunities available to help you demonstrate your services and promote your company as the first choice solution provider in this space.
Discover how to accelerate your NASH candidate development pipeline with access to an unrivalled depth and breadth of cutting-edge NASH science from drug discovery through to late stage clinical development.
Take a look at the complete agenda with 3 parallel streams and speaker line-up of 56 industry experts.
Download the NASH infosheet to find out about NASH drug development, 2017 market predictions and when NASH was first discovered.